Brilique is an oral antiplatelet treatment for acute coronary syndromes (ACS) in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs). Brilique works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce a patient's risk of another cardiovascular event (called atherothrombotic events) such as a heart attack or cardiovascular death. Brilique is the first reversibly-binding oral adenosine diphosphate (ADP) receptor antagonist.
Brilique was developed by AstraZeneca scientists in the late 1990s.For Summary of Product Characteristics and Patient Information Leaflet click this link
2558100 May 2013